Viridian Therapeutics, Inc. (VRDN) Discusses Positive Topline Results from Elegrobart REVEAL-1 Phase III Trial in Active Thyroid Eye Disease Transcript
…
16,318€
-0,86%
Echtzeit-Aktienkurs Viridian Therapeutics Inc.
Bid:
Ask:
Nachrichten zur Viridian Therapeutics Inc. Aktie
Viridian Therapeutics shares fall over 30% after trial data disappoints
Shares of Viridian Therapeutics (NASDAQ:VRDN) fell more than 30% Monday morning following the release of topline results from the company’s…
Viridian Therapeutics stock tumbles despite trial success
Viridian Therapeutics stock tumbles despite trial success…
Viridian Therapeutics: The Song Remains The Same
…
Viridian Therapeutics (VRDN): Stifel sieht 198 % Kurspotenzial - Überzeugende Langzeitdaten aus der Phase-3-Studie THRIVE!
Viridian Therapeutics (VRDN) hat am 20. Mai 2025 positive Langzeitdaten aus der Phase-3-Studie THRIVE veröffentlicht, die den Wirkstoff Veligrotug bei…
Viridian Therapeutics: Veligrotug De-Risked In TED With Hints Of Differentiation
…
Viridian Therapeutics: A Clearer Picture Emerges (Rating Upgrade)
…
Viridian Therapeutics Superior Prospects Make It A Buy
…
Viridian Therapeutics slides on pricing $225M securities offering
…
Viridian Therapeutics, Inc. (VRDN) Q1 2024 Earnings Call Transcript
…